144 related articles for article (PubMed ID: 9802935)
1. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus.
Gaubitz M; Seidel M; Kummer S; Schotte H; Perniok A; Domschke W; Schneider M
J Autoimmun; 1998 Oct; 11(5):495-501. PubMed ID: 9802935
[TBL] [Abstract][Full Text] [Related]
2. Development of an in vitro miniature model to simulate immunoadsorption in patients with systemic lupus erythematosus.
Avenhaus B; Avenhaus W; Schneider M; Domschke W; Gaubitz M
J Clin Apher; 2002; 17(4):183-9. PubMed ID: 12494411
[TBL] [Abstract][Full Text] [Related]
3. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.
Biesenbach P; Schmaldienst S; Smolen JS; Hörl WH; Derfler K; Stummvoll GH
Atheroscler Suppl; 2009 Dec; 10(5):114-21. PubMed ID: 20129388
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption.
Amital H; Heilweil-Harel M; Ulmansky R; Harlev M; Toubi E; Hershko A; Naparstek Y
Rheumatology (Oxford); 2007 Sep; 46(9):1433-7. PubMed ID: 17686790
[TBL] [Abstract][Full Text] [Related]
5. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations.
Vilá LM; Alarcón GS; McGwin G; Friedman AW; Baethge BA; Bastian HM; Fessler BJ; Reveille JD;
Rheumatology (Oxford); 2004 Mar; 43(3):358-63. PubMed ID: 14623949
[TBL] [Abstract][Full Text] [Related]
6. Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus.
Schneider M; Berning T; Waldendorf M; Glaser J; Gerlach U
J Rheumatol; 1990 Jul; 17(7):900-7. PubMed ID: 2213756
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of immunosorption in patients with systemic lupus erythematosus: double blind controlled trial].
Amosova EN; Iaremenko OB; Snezhkova EA; Drannik GV
Ter Arkh; 1997; 69(12):18-22. PubMed ID: 9503527
[TBL] [Abstract][Full Text] [Related]
8. Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.
Muller S; Monneaux F; Schall N; Rashkov RK; Oparanov BA; Wiesel P; Geiger JM; Zimmer R
Arthritis Rheum; 2008 Dec; 58(12):3873-83. PubMed ID: 19035498
[TBL] [Abstract][Full Text] [Related]
9. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases.
Braun A; Sis J; Max R; Mueller K; Fiehn C; Zeier M; Andrassy K
Scand J Rheumatol; 2007; 36(4):291-8. PubMed ID: 17763207
[TBL] [Abstract][Full Text] [Related]
10. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity.
Zandman-Goddard G; Blank M; Langevitz P; Slutsky L; Pras M; Levy Y; Shovman O; Witte T; Doria A; Rovensky J; Shoenfeld Y
Ann Rheum Dis; 2005 Dec; 64(12):1698-702. PubMed ID: 16014675
[TBL] [Abstract][Full Text] [Related]
11. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
[TBL] [Abstract][Full Text] [Related]
12. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus.
Hoffman IE; Lauwerys BR; De Keyser F; Huizinga TW; Isenberg D; Cebecauer L; Dehoorne J; Joos R; Hendrickx G; Houssiau F; Elewaut D
Ann Rheum Dis; 2009 Mar; 68(3):412-5. PubMed ID: 18930995
[TBL] [Abstract][Full Text] [Related]
13. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Leandro MJ; Cambridge G; Edwards JC; Ehrenstein MR; Isenberg DA
Rheumatology (Oxford); 2005 Dec; 44(12):1542-5. PubMed ID: 16188950
[TBL] [Abstract][Full Text] [Related]
14. Anti-dsDNA antibody kinetics during in vivo apheresis in systemic lupus erythematosus patients and in an in vitro apheresis model.
Suzuki K; Taman J; Matsuki Y; Hidaka T; Ishizuka T; Kawakami M; Yabuki T; Kutsuki H; Nakamura H
J Clin Apher; 1996; 11(4):211-6. PubMed ID: 8986867
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus.
Husebye ES; Sthoeger ZM; Dayan M; Zinger H; Elbirt D; Levite M; Mozes E
Ann Rheum Dis; 2005 Aug; 64(8):1210-3. PubMed ID: 15708887
[TBL] [Abstract][Full Text] [Related]
16. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus.
Agarwal S; Harper J; Kiely PD
Lupus; 2009 Apr; 18(5):407-12. PubMed ID: 19318392
[TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: anaemia as a predictor of disease activity and damage accrual.
Bertoli AM; Vilá LM; Apte M; Fessler BJ; Bastian HM; Reveille JD; Alarcón GS;
Rheumatology (Oxford); 2007 Sep; 46(9):1471-6. PubMed ID: 17650522
[TBL] [Abstract][Full Text] [Related]
18. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis.
Spertini F; Leimgruber A; Morel B; Khazaeli MB; Yamamoto K; Dayer JM; Weisbart RH; Lee ML
J Rheumatol; 1999 Dec; 26(12):2602-8. PubMed ID: 10606369
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a therapeutic effect of plasmapheresis in patients with systemic lupus erythematosus.
Jones JV; Cumming RH; Bacon PA; Evers J; Fraser ID; Bothamley J; Tribe CR; Davis P; Hughes GR
Q J Med; 1979 Oct; 48(192):555-76. PubMed ID: 317156
[TBL] [Abstract][Full Text] [Related]
20. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
